Cecilia Pessoa Gingerich

ALD-related hospitalizations grew from 2008 to 2014, especially among women, Asians, Hispanics, and people 50 to 69 years of age.

In a clinical trial, the reSET-O app increased retention in an outpatient opioid use disorder treatment program.

Investigator Anita Clayton, MD, shares insights into the new vortioxetine data and its implications for patients with depression and treatment-emergent sexual dysfunction.

The Spiration Valve System treats emphysema by blocking air from entering diseased areas of the lung.

Can we learn from the last flu season and prepare for the coming peak influenza activity of the current season?

The FDA has approved Dextenza, a dexamethasone ophthalmic insert, for the treatment of ocular pain following ophthalmic surgery.

Ravulizumab dosed every 8 weeks was noninferior to eculizumab given every 2 weeks, but the treatment did not achieve superiority.

The FDA has accepted a Biologics License Application as well as granted Priority Review for the gene therapy that treats spinal muscular atrophy (SMA) Type 1.

While common in adults, congenital cytomegalovirus may cause problems such as hearing and vision loss in newborns.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.

The 4th generation VITROS HIV Combo test has been approved for use with the VITROS ECi/ECiQ Immunodiagnostic System.

Topline data shows that the diabetes medication is non-inferior to placebo with regard to a composite outcome of major adverse cardiovascular events.

Many trials for monoclonal antibody therapies for asthma reported small percentages of African American or Hispanic participants, and some didn’t report racial/ethnic demographics at all.

Jay Edelberg, MD, PhD, of Sanofi and Robert Sanchez, PhD, of Regeneron shared about the recent ODYSSEY OUTCOMES trial of alirocumab (Praluent) and accompanying cost-effectiveness study.

Emapalumab-lzsg was approved by the FDA for the treatment of primary hemophagocytic lymphohistiocytosis in pediatric and adult patients with refractory, recurrent, or progressive disease, or intolerance to conventional therapy.

Emapalumab (Gamifant) is the first FDA-approved treatment for a rare condition that causes life-threatening hyper-inflammation.

EMR data from the 17-18 flu season shows that cell-based influenza vaccines were more effective at preventing influenza-like illness compared to standard egg-based vaccines.

Investigators have found that lowering LDL cholesterol may not be the only way to reduce cardiovascular events—reducing inflammation may be the key to improving outcomes.

Strengths of the DECLARE-TIMI 58 trial included a large primary prevention population, while the nature of the study meant that adherence was likely higher than it would be in a standard setting.

The study showed noninferiority with relation to major adverse cardiovascular events and a reduction of heart failure, though no difference in cardiovascular death compared to placebo. There appear to be renal benefits to dapagliflozin as well.

In addition to a 25% reduction of risk of future cardiovascular events, icosapent ethyl (Vascepa) lowered the risk of cardiovascular death by 20%.

Ezetimibe 10 mg/day significantly reduced the incidence of atherosclerotic cardiovascular events in elderly patients with high LDL cholesterol compared to control.

The updated cholesterol guidelines continue to emphasize a healthy lifestyle for people of all ages and the need for personalized treatment plans. They also lay out a path for escalating treatment when statins aren’t sufficient.

In visits with overweight or obese children with high blood pressure, pediatricians either provide no communication about BP or unclear or dismissive statements, unless SBP is ≥120 mmHg.

The FDA has extended the approved use of Bryhali (halobetasol propionate) Lotion .01% for up to 8 weeks in adults with plaque psoriasis.

The 4th generation VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator has been approved by the FDA for use on the VITROS 5600 Integrated System.

Combining glaucoma medications into a single eye drop could simplify regimens and reduce costs for patients. Investigators found that a combination eye drop also significantly reduced intraocular pressure compared to control.

Patients with diabetic macular edema (DME) switching to aflibercept from ranibizumab improved their BCDA by an average of 5 letters over 9-12 months.

Authors compared investigator assessments to reading center-assessed optical coherence tomography outcomes to evaluate intravitreal aflibercept injection with or without rescue photodynamic therapy.

Ronald Gentile, MD, and colleagues investigated pain-reduction strategies following intravitreal injections. The results have implications for patient experience, physician ratings, and treatment adherence.